徐海,杨洋,汪永生,张晓红

• 1:合肥市第一人民医院心血管内科

摘要(Abstract)：

急性ST段抬高型心肌梗死作为心血管疾病最严重的危急重症之一，发病率高、死亡率高，是急诊介入医师面临的重大挑战之一。目前主流的急诊介入策略是在急性闭塞血管部位置入药物洗脱支架，从而恢复冠状动脉血流供应，减少心肌梗死范围及改善预后等。但是药物洗脱支架的置入也带来一系列问题，如支架内急性血栓形成、支架内再狭窄，血栓负荷重导致支架置入后无复流等。近年来随着“介入无置入”的理念深入人心，药物涂层球囊的应用越来越广泛。目前药物涂层球囊应用于支架内再狭窄和小血管病变已得到了广泛的认可，但其在急性ST段抬高型心肌梗死介入治疗中的疗效仍研究甚少，本文主要对目前国内外关于药物涂层球囊在急性ST段抬高型心肌梗死介入治疗中的可行性、安全性及有效性等方面加以综述，旨在指导急诊介入策略的选择，改善患者预后。

关键词(KeyWords)： 药物涂层球囊;药物洗脱支架;急性ST段抬高型心肌梗死

Abstract:

Keywords:

基金项目(Foundation): 安徽省卫生健康科研项目（AHWJ2023Bac20115）;; 安徽医科大学校青年基金项目（2021xkj105）;; 合肥市卫生健康委2021年度应用医学研究项目（Hwk2021zd）

作者(Author): 徐海,杨洋,汪永生,张晓红

参考文献(References)：

• [1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.DOI:10.3760/cma.j.issn.0253-3758.2019.10.003.
• [2]Stone SG,Serrao GW,Mehran R,et al.Incidence,predictors,and implications of reinfarction after primary percutaneous coronary intervention in ST-segmentelevation myocardial infarction:the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial[J].Circ Cardiovasc Interv,2014,7(4):543-551.DOI:10.1161/CIRCINTERVENTIONS.114.001360.
• [3]Vink MA,Dirksen MT,Suttorp MJ,et al.5-year followup after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute STsegment elevation myocardial infarction:a follow-up study of the PASSION(Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation)trial[J].JACC Cardiovasc Interv,2011,4(1):24-29.DOI:10.1016/j.jcin.2010.11.003.
• [4]乔树宾,田宏伟.“介入无植入”新理念——药物涂层球囊临床应用新进展[J].中国循环杂志,2018,33(8):729-731.DOI:10.3969/j.issn.1000-3614.2018.08.001.
• [5]《药物涂层球囊临床应用中国专家共识(第二版)》专家组.药物涂层球囊临床应用中国专家共识(第二版)[J].中国介入心脏病学杂志,2023,31(6):413-426.DOI:10.3969/j.issn.1004-8812.2023.06.003.
• [6]Axel DI,Kunert W,Goggelmann C,et al.Paclitaxel inhibits arterial smooth muscle cell proferation and migration in vitro and in vivo using local drug delivery[J].Circulation,1997,96(2):636-645.DOI:10.1161/01.cir.96.2.636.
• [7]Scheller B,Speck U,Schmitt A,et al.Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation[J].J Am Coll Cardiol,2003,42:1415-1420.DOI:10.1016/s0735-1097(03)01056-8.
• [8]Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J],N Engl J Med,2006,335(20):2113-2124.DOI:10.1056/NEJMoa061254.
• [9]Jeger RV,Eccleshall S,Wan Ahmad WA,et al.Drugcoated balloons for coronary artery disease:third report of the International DCB Consensus Group[J].JACC Cardiovasc Interv,2020,13(12):1391-1402.DOI:10.1016/j.jcin.2020.02.043.
• [10]Jing QM,Zhao X,Han YL,et al.A drug-eluting Balloon for the treatment of coronary bifurcation lesions in the side branch:a prospective multicenter randomized(BEYOND)clinical trial in China[J].Chin Med J(Engl),2020,133(8):899-908.DOI:10.1097/CM9.0000000000000743.
• [11]Yu X,Ji F,Xu F,et al.Treatment of large de novo coronary lesions with paclitaxel-coated balloon only:results from a Chinese institute[J].Clin Res Cardiol,2019,108(3):234-243.DOI:10.1007/s00392-018-1346-8.
• [12]王春良,张迎中,仲宝华.血管内超声指引下药物洗脱球囊治疗冠状动脉原位原发大血管病变的疗效观察[J].川北医学院学报,2024,39(4):551-554.DOI:10.3969/j.issn.1005-3697.2024.04.027.
• [13]Madanchi M,Bossard M,Majcen I,et al.Outcomes following coronary chronic total occlusion revascularization with drugcoated balloons[J].J Invasive Cardiol,2024,36(3).DOI:10.25270/jic/23.00260.
• [14]Wang X,Yang X,Lu W,et al.Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo coronary chronic total occlusion intervention:a multicenter observational study[J].Front Cardiovasc Med,2023,10:1045859.DOI:10.3389/fcvm.2023.1045859.
• [15]Sati P,Sharma E,Dhyani P,et al.Paclitaxel and its semisynthetic derivatives:comprehensive insights into chemical structure,mechanisms of action,and anticancer properties[J].Eur J Med Res,2024,29(1):90.DOI:10.1186/s40001-024-01657-2.
• [16]Scheller B,Speck U,Bohm M.Prevention of restenosis:is angioplasty the answer?[J].Heart,2007,93(5):539-541.DOI:10.113 6/hrt.2007.118059.
• [17]Yerasi C,Case BC,Forrestal BJ,et al.Drug-coated balloon for de novo coronary artery disease:JACC state-of-the-art review[J].J Am Coll Cardiol,2020,75(9):1061-1073.DOI:10.1016/j.jacc.2019.12.046.
• [18]Vos NS,Dirksen MT,Vink MA,et al.Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam(PAPPA):one-year clinical outcome of a pilot study[J].Euro Intervention,2014,10(5):584-590.DOI:10.4244/EIJV10I5A101.
• [19]Vos NS,Fagel ND,Amoroso G,et al.Paclitaxelcoated balloon angioplasty versus drug-eluting stent in acute myocardial infarction:the REVELATION randomized trial[J].JACC Cardiovasc Interv,2019,12(17):1691-1699.DOI:10.1016/j.jcin.2019.04.016.
• [20]Niehe SR,Vos NS,Van Der Schaaf RJ,et al.Two-year clinical outcomes of the REVELATION study:sustained safety and feasibility of paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction[J].J Invasive Cardiol,2022,34(1):E39-E42.DOI:10.25270/jic/20.00741.
• [21]Niehe SR,Vos NS,Van Der Schaaf RJ,et al.5-year clinical outcomes of paclitaxel-coated balloon angioplasty vs.DES in acute MI:the REVELATION trial[J].JACC Cardiovasc Interv,2024,17(9):1185-1186.DOI:10.1016/j.jcin.2024.01.288.
• [22]Merinopoulos I,Gunawardena T,Corballis N,et al.Assessment of paclitaxel drug-coated balloon only angioplasty in STEMI[J].JACC Cardiovasc Interv,2023,16(7):771-779.DOI:10.1016/j.j cin.2023.01.380.
• [23]Hao X,Huang D,Wang Z,et al.Correction to:study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction[J].J Cardiothorac Surg,2021,16(1):247.DOI:10.1186/s13019-021-01629-1.
• [24]杨帮国,张紫微,尹晓梅,等.准分子激光冠状动脉成形术联合血栓抽吸术成功治疗急性心肌梗死合并右冠状动脉大量血栓3例[J].中国介入心脏病学杂志,2023,31(12):955-960.DOI:10.3969/j.issn.1004-8812.2023.12.011.
• [25]Bhindi R,Kajander OA,Jolly SS,et al.Culprit lesionthrombus burden after manual thrombectomy or percutaneouscoronary intervention-alone in ST-segment elevation myocardialinfarction:the optical coherence tomography substudy of the TOTAL(ThrOmbecTomy versus PCI ALone)trial[J].Eur Heart J,2015,36(29):1892-1900.DOI:10.1093/eurheartj/ehv176.
• [26]王宁远,冯欢欢,王威,等.光学相干断层成像指导准分子激光联合药物涂层球囊治疗复发性支架内再狭窄的初步研究[J].中国介入心脏病学杂志,2023,31(8):579-584.DOI:10.3969/j.issn.1004-8812.2023.08.003.
• [27]Tonomura D,Shimada Y,Yamanaka Y,etal.Laser vaporization of atherothrombotic burden before drug-coated balloon application in ST-segment elevation myocardial infarction:two-year outcomes of the laser-DCB trial[J].Catheter Cardiovasc Interv,2022,99(6):1758-1765.DOI:10.1002/ccd.30149.
• [28]Kondo Y,Ishikawa T,Shimura M,et al.Cardiovascular outcomes after paclitaxel-coated balloon angioplasty versus drug-eluting stent placement for acute coronary syndrome:a systematic review and meta-analysis[J].J Clin Med,2024,13(5):1481.DOI:10.3390/jcm13051481.
• [29]Changal K,Patel M,Mir T,et al.Drug-coated balloons versus drug-eluting stents in ST elevation myocardial infarction:a meta-analysis[J].Am J Cardiol,2020,133:174-175.DOI:10.1016/j.amjcard.2020.07.026.
• [30]Fang Z,Ji J,He S,et al.Drug-coated balloon vs.drug-eluting stent in acute myocardial infarction:a systematic review and updated meta-analysis[J].Anatol J Cardiol,2023,27(8):444-452.DOI:10.14744/AnatolJCardiol.2023.2953.
• [31]张大鹏,王乐丰,刘宇,等.药物涂层球囊与药物洗脱支架治疗冠状动脉原发病变的疗效与安全性比较[J].中华心血管病杂志,2020,48(7):600-607.DOI:10.3760/cma.j.cn112148-20200327-00254.